4D Molecular Therapeutics Faces Market Challenges Amid Stock Decline 4D Molecular Therapeutics (FDMT) has seen its stock hit a 52-week low of $3.92, reflecting a sharp 86.16% drop over the past year. Analysts have mixed views, with price targets ranging from $6 to $65. Despite positive clinical trial data for its gene therapy candidate 4D-150, concerns over market durability persist.12